Journal
EXPERT OPINION ON INVESTIGATIONAL DRUGS
Volume 17, Issue 6, Pages 939-944Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1517/13543784.17.6.939
Keywords
angiogenesis; enzastaurin; protein kinase C-beta inhibitor
Categories
Ask authors/readers for more resources
Background: Enzastaurin is a novel antineoplastic and antiangiogenic agent that acts through inhibition of protein kinase C (PKC). Objective: This review summarizes the scientific rationale and current clinical evidence for the use of enzastaurin in oncology. Methods: We performed a systematic review of the literature using the keywords protein kinase C-beta and enzastaurin in order to characterize the therapeutic target PKC-beta. We then reviewed the in-vitro, Phase I, and Phase II data for enzastaurin with a focus on hematologic malignancies. Results/conclusions: After preliminary Phase I trials established a favorable toxicity profile, enzastaurin has been studied in completed and ongoing Phase II and III studies in solid and hematologic malignancies, including B-cell lymphomas where the rationale for its use is most promising.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available